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ABSTRACT
Two recently detected viruses, human metapneumovirus (hMPV) and coronavirus NL63 (HCoV-NL63),
have been associated with acute respiratory tract infections, particularly in young children. This study
investigated the frequency of hMPV and HCoV-NL63 infections in Swedish children by screening 221
nasopharyngeal aspirates, collected between November 2003 and May 2005, from 212 children attending
the paediatric department of a county hospital in Sweden or submitted from local general practitioners.
The samples were originally submitted to be tested for respiratory syncytial virus (RSV), and were
examined retrospectively for hMPV and HCoV-NL63 by RT-PCR. Of the 212 patients, 101 were positive
for RSV (48%), 22 (10%) were positive for hMPV, and 12 (6%) were positive for HCoV-NL63. The
frequency of HCoV-NL63 infection increased from 1% in 2003–2004 to 10% in 2004–2005. Sequence
analysis of parts of the coronavirus genomes showed considerable similarity to the HCoV-NL63
prototype sequence. The study demonstrated that HCoV-NL63 and hMPV occur in south-west Sweden
with essentially the same frequency, seasonal distribution and clinical characteristics as have been
reported in other countries.
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INTRODUCTION
Respiratory syncytial virus (RSV) is the most
common viral cause of lower respiratory tract
infection in young children, followed by para-
inﬂuenza virus, inﬂuenza virus and other viruses,
but no aetiological cause is identiﬁed for many
cases of infection [1–5]. The number of unidenti-
ﬁed causes has decreased following the discovery
of human metapneumovirus (hMPV) in 2001 [6],
and may be reduced still further following the
discovery of human coronavirus NL63 (HCoV-
NL63) in 2004 [7,8].
Infections with hMPV have been reported in
many countries, suggesting a worldwide distri-
bution [9–17]. hMPV seems to cause a range of
symptoms and respiratory tract diseases similar
to those caused by RSV, mainly in infants and
elderly individuals. The epidemiology of hMPV
infections appears to be seasonal, with a peak in
late winter and early spring. In the case of
HCoV-NL63, there have been a number of
worldwide reports that describe an association
with both upper and lower respiratory tract
infections, and speciﬁcally with clinical croup
[18–26].
The present study presents data obtained with
221 nasopharyngeal aspirates collected between
November 2003 and May 2005 from 212 children
with symptoms of upper and lower respiratory
tract infections in Halmstad, Sweden. The sam-
ples were analysed for the presence of RSV,
hMPV and HCoV-NL63. To simplify the diag-
nostic procedures on bronchiolitis samples, the
RSV, hMPV and HCoV-NL63 real-time RT-PCRs
were performed simultaneously on the same
platform.
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MATERIALS AND METHODS
Clinical specimens and patient data
Between 1 November 2003 and 31 May 2005, nasopharyngeal
aspirates submitted for RSV testing were examined consecu-
tively. RNA was separated from these samples (see below) and
stored immediately at )70C. More than 95% of the specimens
originated from the outpatient clinic and inpatient wards of
the Paediatric Department of Halmstad Hospital, and the
remainder (<5%) from general practitioners in the county of
Halland, Sweden. All specimens were obtained from patients
aged <10 years with symptoms of respiratory tract infection.
Clinical and demographical patient data were obtained from
the medical records of the patients and recorded on a standard
form. Fig. 1 shows the age distribution of the patients; >90% of
the samples were taken from patients aged <1 year.
RNA extraction
RNA was extracted from c. 140 lL of each nasopharyngeal
aspirate with a QiaAmp Viral RNA Mini Kit (Qiagen, Hilden,
Germany) in accordance with the manufacturer’s instructions.
RNA extraction and storage at )70C were completed on the
day that the sample arrived at the laboratory. The dates of
sample collection and arrival at the laboratory were identical
for 80% of the samples, while the remaining 20% had been
stored at 4C overnight and were delivered the following day.
Conventional RT-PCR and sequencing for HCoV-NL63
To detect HCoV-NL63 RNA, two separate nested PCRs were
performed, following one combined RT step. The PCRs
ampliﬁed sequences in the replicase and N genes [7]. Reverse
transcription was performed using 20 lL of each of the RNA
preparations. The 40-lL RT-PCR mixes contained MMLV-
reverse transcriptase (Invitrogen, Carlsbad, CA, USA) 5 U ⁄lL,
500 lM dNTPs, 10 mM Tris-HCl, pH 8.3, Triton-X 0.1% v ⁄v,
5.5 mM MgCl2, 50 mM KCl and the two RT primers repSZ-RT
and N3-RT (Table S1; see Supplementary material) at
250 pg ⁄ lL. The reaction mix was incubated at 37C for 90 min.
In the ﬁrst-round PCR, 20 lL of the cDNA was added to
ﬁnal reaction volumes of 50 lL containing AmpliTaqGold
0.025 U ⁄ lL, 50 lM dNTPs, 12 mM Tris-HCl, pH 8.3, bovine
serum albumin 60 ng ⁄lL, 1 mM MgCl2, 30 mM KCl and each
primer (Table S1) at 1 ng ⁄ lL. Nested PCRs were performed
with 2.5 lL of the product from the ﬁrst-round PCRs. Final
concentrations in the 50-lL reaction volumes were AmpliTaq-
Gold 0.02 U ⁄ lL, 100 lM dNTPs, 20 mM Tris-HCL, pH 8.3,
bovine serum albumin 100 ng ⁄ lL, 2 mM MgCl2, 50 mM KCl
and each primer at 1 ng ⁄ lL (Table S1).
Thermocycling conditions for the replicase gene PCR and
the N gene PCR were identical. The ﬁrst- and the second-
round PCRs differed only in the number of cycles, and
comprised 95C for 5 min, followed by 35 cycles (ﬁrst-round
PCR) or 25 cycles (second-round PCR) of 95C for 1 min, 55C
for 1 min and 72C for 2 min, and ﬁnally 72C for 10 min. PCR
products were separated by electrophoresis on agarose gels
and visualised by staining with ethidium bromide. Positive
and negative controls were used in each RT-PCR and in each
PCR. The positive control consisted of RNA isolated from
passage of HCoV-NL63 in LLC-MK2 cells [7], using an amount
of RNA equivalent to 105)106 RNA copies for the RT-PCR and
subsequent PCRs; the negative control was sterile water.
Real-time RT-PCR assay for HCoV-NL63
A 98-bp segment of the N gene was ampliﬁed using a one-step
real-time RT-PCR and primers, as described by Fouchier et al.
[8]. Brieﬂy, the ﬁnal volume of 25 lL contained 3 lL of RNA
preparation, 800 nM each primer, 300 nM probe, 1· TaqMan
Universal PCR Master Mix and 1· MultiScribe and RNAse
Inhibitor (TaqMan One-Step RT-PCR Master Mix Reagents;
Roche, Branchburg, NJ, USA). Cycling parameters comprised
30 min at 48C, 10 min at 95C, and 45 cycles of 15 s at 95C
and 1 min at 60C. Reverse transcription of RNA, ampliﬁcation
and detection of cDNA were performed using an ABI Prism
7000 TaqMan instrument (Applied Biosystems, Foster City,
CA, USA). The positive control was the same material used for
the conventional PCR, but at a concentration of 30–300 RNA
copies ⁄PCR. Part of the 5¢-region of the spike insert gene was
sequenced if a PCR product for this gene was generated with
the primers listed in Table S1; if not, the PCR product from the
real-time RT-PCR assay for HCoV-NL63 was used as the
template for sequencing. The PCR products were sequenced
directly using a BigDye Terminator v.3.1 Cycle Sequencing Kit
(Applied Biosystems) with an ABI 3100 Genetic Analyser
(Applied Biosystems) at the BioMedical Laboratory, Furulund,
Sweden. Both sense and anti-sense strands of the PCR
products were sequenced.
Real-time RT-PCR assay for hMPV
A segment of the F genewas ampliﬁedwith a one-step real-time
RT-PCR based on the method described by Maertzdorf et al.
[27],whichdetects all knownhMPVgenotypes. In brief, the ﬁnal
25-lL volume contained 3 lL of RNApreparation, 300 nM both
primers (Table S1), 200 nM probe, 1· TaqMan Universal PCR
Master Mix and 1· MultiScribe and RNAse Inhibitor. As this
assay was performed in combination with the HCoV-NL63 and
the RSV assays, the cycling parameters and the instrumentwere
the same as those described for HCoV-NL63.
The positive control consisted of RNA transcribed in vitro
with nucleotide sequences derived from an hMPV isolate of
lineage A (kindly provided by L. P. Nielsen, University
Hospital, Odense, Denmark). The PCR product generated by
the two diagnostic primers was cloned into pGEM vector
(Promega, Madison, WI, USA) under the control of a T7
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Fig. 1. Age distribution of patients included in the study.
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promoter. Run-off transcripts were generated using the Ribo-
probe in-vitro transcription system (Promega) and were
quantiﬁed by measuring the absorption at A260 in a spectro-
photometer. The RNA transcripts were then diluted for use as
a positive control, with 90 copies ⁄RT-PCR. This corresponds to
a concentration ten-fold higher than the detection limit. This
concentration was also used as a control for inhibitors in
specimens that tested negative in all PCRs.
Real-time RT-PCR assay for RSV
A multiplex assay for RSV A and RSV B used primers and
probes from the respective N genes, both of which are highly
conserved. The separate RT-PCR and PCR steps, as described
by van Elden et al. [28], were combined in a one-step reaction.
In brief, the ﬁnal 25-lL volumes contained 3 lL of RNA
preparation, 900 nM each primer (Table S1), 200 nM each
probe, 1· TaqMan Universal PCR Master Mix and 1· Multi-
Scribe and RNAse Inhibitor. As this assay was performed in
combination with the HCoV-NL63 and the hMPV assays, the
cycling parameters and the instrument used were identical to
those described for HCoV-NL63.
Run-off transcripts for RSV A and RSV B were used as
positive controls. The nucleotide sequences originated from
routine samples and had identical sequences for all primer and
probe binding sites, as determined by sequencing the PCR
products that were used for cloning. The cloning and in-vitro
transcription procedures were the same as described for
hMPV. The RNA transcripts were then diluted for use at a
concentration ten-fold higher than the detection limit.
RESULTS
Evidence of RSV, hMPV and HCoV-NL63 in
nasopharyngeal aspirates
RSV was detected most frequently, with 101 (48%)
of 212 patients yielding positive results. hMPVwas
detected in 22 (10%) patients, three of whom
showed positive results for both RSV and hMPV.
HCoV-NL63 RNA was detected in 12 (6%)
patients, including one co-infected with hMPV.
Inhibitionwas observed for one of the 221 samples.
The RNA preparation from this sample was dilut-
ed ten-fold and re-tested in both PCRs. Following
dilution, no inhibition was observed, but the
sample continued to yield negative results.
Evidence of HCoV-NL63 infection
Of the 12 samples from 12 individuals positive for
HCoV-NL63 RNA, one sample was taken in the
winter season 2003–2004, while the other 11 were
collected between December 2004 and February
2005 (Fig. 2). Eight samples were also positive
according to the two conventional HCoV-NL63
PCRs. The remaining four samples generated
positive results only with the real-time PCR.
The two full genome sequences of HCoV-NL63
in GenBank showed substantial differences in the
5¢ region of the spike gene. It was possible to
generate and sequence a PCR product from this
gene for ten of the 12 positive samples (GenBank
accession numbers: AY902242 and DQ231158–
DQ231166). These spike gene sequences showed
0–7 substitutions compared with the NC005831
prototype sequence, which represents the
sequence of the ﬁrst HCoV-NL63 strain to be
detected, and 62–65 substitutions compared with
the prototype of the other genetic lineage
AY518894 (Fig. 3). PCR products from the
remaining two samples that tested positive only
in the real-time assay were also sequenced and
were shown to be HCoV-NL63 sequences.
False-positive reactions in the HCoV-NL63
replicase gene PCR
All samples were run on gels after the second
round of PCRs. Two of the 221 samples, from two
different individuals, generated amplicons in the
replicase gene PCR that had the same size as the
positive control amplicon. No amplicons were
generated by the N gene PCR from these two
samples, but gel electrophoresis of the ﬁrst-round
replicase gene PCR showed products of the same
size as the positive control after the second-round
PCR (169 bp). These products were still detectable
after the second-round replicase gene PCR.
Sequencing of the two products revealed that they
comprised part of the human X-chromosome.
Alignment of the two ﬁrst-round primers to this
sequence revealed two probable target sites with
good 3¢-attachment (10-bp identity for the repSZ1
primer and 9-bp identity for the repSZ3 primer).
The predicted size of the resulting ampliﬁcation
productwas 174 bp,which is close to the size of the
second-round product of the HCoV-NL63 assay
(169 bp).
Comparison between the conventional and real-
time RT-PCRs
The two conventional RT-PCRs were unable to
detect <100–1000 RNA copies of HCoV-
NL63 ⁄PCR, while the real-time assay yielded
positive results from 0.3 — 3 RNA copies ⁄PCR.
This difference in sensitivity is consistent with the
ﬁnding that four samples that were positive in the
real-time assay, and had sequences matching with
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HCoV-NL63, did not yield positive results in the
two conventional PCRs. The two false-positive
results in the conventional replicase gene PCR
also resulted in a decreased speciﬁcity compared
with the two other methods.
Clinical data
Of the 22 positive samples from 22 individuals
detected by the real-time RT-PCR assay for hMPV,
eight were collected between January and May
2004, and the remaining 14 between January and
April 2005, with February being the peak month
during both periods (Fig. 2). Three of the 22 hMPV-
positive samples also containedRSVRNA, and one
sample also contained HCoV-NL63 RNA.
The medical ﬁles of 203 patients were available
(100 from 2003–2004 and 103 from 2004–2005).
The patients were divided into four groups: 85
who were only RSV-positive (RSV group); 18 who
were only hMPV-positive (hMPV group); 11 who
were only HCoV-NL63-positive (HCoV-NL63
group); and 85 who were negative for all three
viruses (negative group). The clinical data for the
patients in these groups are summarised in
Table 1. Three patients who were positive for
both RSV and hMPV, together with one patient
who was positive for both hMPV and HCoV-
NL63, were not included in this analysis. The
clinical features of the 12 patients who were
positive for HCoV-NL63 are shown in Table 2.
DISCUSSION
This study investigated the frequency of HCoV-
NL63 and hMPV infections among a group of
children with symptoms of respiratory tract
infection in Sweden during two consecutive
winter seasons. HCoV-NL63 was detected at
an overall frequency of 6% (1% during
2003–2004 and 10% during 2004–2005). This
observation of annually changing frequencies is
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consistent with the ﬁndings from the studies of
Moes et al. [22] and Arden et al. [19]. In agree-
ment with other reports, there was a seasonal
distribution of HCoV-NL63 infections
[18,22,25,26,29], with most HCoV-NL63 infec-
tions occurring before RSV and hMPV infections
during 2004–2005 (Fig. 2). However, it was not
possible to compare the seasonal differences
with other studies because of the limited data
available and the different climates at the
various study sites.
All of the HCoV-NL63 isolates belonged to the
same genetic lineage. This may reﬂect the homo-
geneity of the circulating viruses within one
season. Other studies have shown co-circulation
of genetically more diverse variants of the virus
within a single season [19,20,22,25,29]. As little is
known concerning the genetic heterogeneity of
the virus, it is possible that the RT-PCR protocols
used were not optimal for all HCoV-NL63 vari-
ants, and that both the frequency and the variab-
ility may be greater than observed. However,
since three PCR protocols that targeted two
presumably well-conserved genes were used,
false-negative samples should be rare.
The mean age (2 months) of patients in the
HCoV-NL63 group was low compared with most
previous studies, but the overall age of the patient
groups was low (Fig. 1), and might reﬂect the
method of selecting patients at the paediatric
department. Children aged <1 year with symp-
toms of respiratory tract infection are usually
Table 1. Clinical data for patients included in the studya
RSV
group
(n = 85)
hMPV
group
(n = 18)
HCoV-NL63
group
(n = 11)
Negative
group
(n = 85)
Mean age (median) in months 6 (3) 7 (5) 2 (2) 4 (3)
Gender
Female 40 6 3 35
Male 45 12 8 50
Fever (at least once >38C) 51% 39% 18% 32%
Chest X-rays taken
(irrespective of results)
26% 22% 9% 24%
Antibiotic treatment given 17% 22% 9% 18%
Duration of hospital
stay in days
3.7 1.6 1.5 1.9
aPatients who were positive for more than one virus are not included in this
analysis.
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Fig.3. Phylogenetic analysis of the
HCoV-NL63 isolates described in
this study. Phylogenetic analysis
was performed using the neigh-
bour-joining method of the MEGA
program. The nucleotide distance
matrix was generated by Kimura’s
two-parameter estimation [39]. Boot-
strap re-sampling (1000 replicates)
was used to provide approximate
CIs on individual branches. Boot-
strap values >70 are indicated.
Sequences from several HCoV-
NL63 strains that have been sub-
mitted previously to GenBank
from previous studies (AY46451–
AY46458, AY675541–AY675553 and
AY66005–AY66010) have been inclu-
ded in the analysis.
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treated in hospital, while older children are
treated at home by general practitioners. Most
previous studies have contained a larger propor-
tion of older children, who account for a sub-
stantial proportion of HCoV-NL63 infections. The
present study contained few samples from chil-
dren aged >1 year, and only 11 patients were
positive for HCoV-NL63 alone, so that compar-
isons with previous studies are not valid.
The clinical symptoms associated with NL63
infections have yet to be established. Some studies
have found that HCoV-NL63 infections are pre-
dominantly severe lower respiratory tract infec-
tions, mainly in patients with underlying diseases
[8,22,29], while other studies have reported mild
respiratory tract infections in previously healthy
patients [7,19–21,26]. The clinical features in the
HCoV-NL63 group in the present study (Table 1
and Table 2) were indicative of a lower disease
severity than for RSV and hMPV infections.
However, only nasopharyngeal aspirates of chil-
dren aged <10 years were studied. The causative
role of HCoV-NL63 in different clinical manifes-
tations and age groups has yet to be established.
Therefore, it is important to conduct a wide range
of retrospective and prospective studies in order
to obtain a better estimate of the incidence and
clinical effects of HCoV-NL63 in different popula-
tions.
Two false-positive PCR results were observed
with the replicase gene PCR. Both products were
sequenced and showed the same degree of
homology with part of the human X-chromosome.
The PCR signal generated was quite weak and
was not observed with any of the other samples.
Considering that all the samples will have con-
tained X-chromosome DNA, the fact that only
two of 221 samples tested positive could reﬂect
sequence differences at the primer binding sites of
the X-chromosome, or simply different amounts
of X-chromosome DNA in the samples. The
replicase gene PCR could be used as a screening
tool, but all positive ﬁndings should be conﬁrmed
by sequencing. The higher sensitivity of real-time
RT-PCR in comparison with the two conventional
RT-PCRs, together with a more convenient pro-
tocol, supports the use of this method as a
screening tool.
In addition to HCoV-NL63, this is the ﬁrst
report of hMPV infections in Sweden. The ﬁnding
that 10% of the samples contained hMPV RNA is
comparable with the results of previous studies
that detected hMPV in 2.9–17.5% of respiratory
samples from non-selected groups of children
[10,15–17,30–36]. Two reports from Finland (po-
sitivity rates of 4% and 8%), one from Denmark
(positivity rate of 2.9%) and two from Norway
show that the virus has been circulating in
Scandinavia [11–13,37,38].
The present study indicated that hMPV infec-
tions have the same seasonal distribution as RSV
infections (Fig. 2). All the aforementioned studies
documented hMPV during the winter and spring
months, and some investigators have observed
Table 2. Clinical features of the 12 patients who were positive for human coronavirus NL63
Sample
number
Date of
collection Gender Age
Underlying
conditions Symptoms
Physical examination
ﬁndings Other information Discharge diagnosis
10614 040127 M 3 weeks None Rhinitis, dyspnoea No focus of infection Upper respiratory tract infection
25188 041222 M 3 weeks None Rhinitis, dyspnoea,
vomiting
Crepitations, rhonchi Adrenaline inhalations Bronchiolitis
25190 041222 M 1 month None Rhinitis, dyspnoea Tachypnoea, crepitations,
pharyngitis
Adrenaline inhalations Bronchiolitis
25205 041226 M 2 months None Dyspnoea, fever, apathy Crepitations, rhonchi,
rash
Adrenaline inhalations Viral infection
25222 041228 F 3 months None Rhinitis, fever Fever Upper respiratory tract infection
25230 041230 M 3 months None Rhinitis, cough, secretion
from right eye
Bell’s palsy, right side Onset of palsy probably
weeks before rhinitis
Upper respiratory tract infection,
Bell’s palsy
36024 050105 F 4 months None Dyspnoea, vomiting Crepitations Upper respiratory tract infection
36031 050110 M 2 months Pre-term
week 28, RDS
Apathy, cough, dyspnoea Pale, dehydrated CXR: bilateral apical
inﬁltrates, CPAP
ventilation
Upper respiratory tract infection
36089 050120 F 4 months None Cough, dyspnoea Tachypnoea, crepitations Upper respiratory tract infection
36116 050131 M 1 month None Vomiting, cough No focus of infection Hospitalisation for
pylorostenosis
Pylorostenosis, upper respiratory
tract infection
36150 050207 M 4 weeks None Rhinitis, dyspnoea Pharyngitis, fever Upper respiratory tract infection
36164 050210 F 2 years Pre-term
week 24,
RDS, repeated
asthmatic
bronchiolitis
Dyspnoea, insufﬁcient
effect of asthma
medication
Crepitations, rhonchi CXR: unilateral basal
inﬁltrate, co-infection
with hMPV
Asthma, infection triggered
RDS, respiratory distress syndrome; CXR, chest X-ray; CPAP, continuous positive airways pressure; hMPV, human metapneumovirus.
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differences in the age distribution between RSV-
infected and hMPV-infected children [10,36]. The
present study observed a similar median age in
the group of hMPV-infected children to that in the
group of RSV-infected children, as reported also
by van den Hoogen et al. [9].
The pathogenicity of hMPV compared with
RSV is also a matter for debate. Williams et al.
[10] did not observe differences in chest X-ray
and hospitalisation rates. Other studies have
found lower hospitalisation rates, a shorter
duration of symptoms and lower illness scores
for hMPV-positive patients [9,35]. The present
study also found evidence of shorter hospitali-
sation periods with hMPV infection, while the
similar rate at which chest X-rays were taken
and the low frequency of antibiotic treatment
strengthen the observations made by Williams
et al. [10]. To determine the incidence and
clinical features of HCoV-NL63 and hMPV
infection, testing was limited to these two
viruses and RSV. Thus, the overall burden of
infection caused by respiratory tract pathogens
was not investigated, and it is possible that
some co-infections with other viruses or bacteria
were not detected.
The availability of simple and quick methods
suggests that combined testing of RSV and hMPV
should be considered for routine diagnostic use.
Both viruses are present in the same patient
groups and cannot be differentiated clinically.
Cohorting strategies for both viruses to prevent
nosocomial spread can be based on this
technique. The combined real-time assay can be
complemented with the real-time assay for
HCoV-NL63 so that additional diagnostic and
clinical knowledge of its role in different clinical
manifestations can be gained.
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